FzioMed's FDA dispute panel delayed for new data submission

The dispute resolution panel slated to review the FDA's rejection of FzioMed's Oxiplex spinal surgery gel is postponed so the FDA can review additional data.

FzioMed said today that a dispute resolution panel slated for next month for its Oxiplex spinal surgery gel has been postponed so the FDA can review more clinical data.

Food & Drug Administration (FDA), FzioMed

News Well, Pre-Market Approval (PMA), Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1nBdka9